Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Mark Mcdade currently holds 10,000 shares of Tourmaline Bio, Inc. (TRML), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Mark Mcdade has been a net seller of TRML stock. They have purchased $3.8M and sold $5.0M worth of shares.
Mark Mcdade's most recent insider trade was on Oct 28, 2025, when they sold 518 shares at $0.00 per share.
Mark Mcdade serves as Executive at Tourmaline Bio, Inc. (TRML). They have executed 126 insider transactions totaling $8.8M over their tenure at the company.
Mark Mcdade holds the position of Executive at Tourmaline Bio, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 21 years and currently hold a stake valued at $0.
Mark Mcdade has shown a selling trading pattern, with $3.8M in total purchases and $5.0M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Mark Mcdade was on Jan 29, 2024, when they purchased $3.3M worth of TRML shares. This transaction involved 100,000 shares at $32.50 per share.
Mark Mcdade currently owns 10,000 shares of Tourmaline Bio, Inc. (TRML), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Mark Mcdade's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Mark Mcdade has 126 Form 4 filings on record as an insider at Tourmaline Bio, Inc..
Set alerts for Mark Mcdade and 40,000+ other insiders.